[1852] Distinguishing Adenocarcinoma from Squamous Cell Carcinoma in the Lung Using Double Stains: Napsin A and p63 and TTF-1 and CD141

D Tacha, D Zhou, RL Henshall-Powell. Biocare Medical, Concord

Background: To distinguish primary lung tumors from metastatic tumors to the lung, a panel of antibodies is used. The current FDA-approved standard treatment for non-small cell lung cancer is Carboplastin/Taxol/Avastin. However, based upon survival benefit; patients with squamous cell carcinoma (SCC) should not receive Avastin due to a 30% mortality rate by fatal hemoptysis. The use of TTF1, CK7 and p63 has been used to differentiate primary lung cancer from metastases. Thrombomodulin (CD141) has been shown to be sensitive for SSC and Napsin A has been shown to be a specific marker of lung adenocarcinoma (LADC); however, information on specificity of Napsin A from other cancer sites is desirable. We investigated the specificity and sensitivity of Napsin A on a wide spectrum of normal and neoplastic tissues including lung cancers and double stain protocols with Napsin A, CD141, TTF1 and p63 were developed.
Design: Tissue microarrays (TMA) were constructed from archival normal and neoplastic tissues. TMAs were deparaffinized in the usual manner and antigen retrieval was performed. Napsin A was evaluated for specificity and sensitivity. Lung cancer TMAs were evaluated with double-stain procedures for TTF1, CD141, p63 and Napsin A.
Results: Napsin A was positive in 50% of renal cell carcinomas; 21% of thyroid cancers; 2% of ovarian cancers; 0% of cervical cancer (squamous cell) and 16% of cervical adenocarcinomas. Breast, colon, prostate, bladder, seminoma, liver, lymphoma, leiomyosarcoma and pancreatic cancers were all negative. In normal tissues, only lung and kidney were positive. In LADC, Napsin A demonstrated equal sensitivity to TTF1 (77.4%) but was slightly more specific (Table 1). Napsin A was negative in 93.4% of SSC, while CD141 and p63 were positive (89.8% & 75%) in SCC respectively. There were 2 cases of SCC that did not express p63 or CD141, but expressed Napsin A and TTF1.

Table 1
Lung CancersAntibodyCasesPositive
Adenocarcinomap63312
TTF13124
Napsin A3124
TTF1 + Napsin A3126
CD141315
SCCp634943
TTF1494
Napsin A493
CD1414933
p63 + CD1414944
Adenosquamous Cell Carcinomap6374
TTF175
Napsin A75
CD14174



Conclusions: Double stains provide invaluable information when target antigens are visualized on a single slide. We demonstrated that the combination of Napsin A and TTF1 are a highly-specific in a large proportion of primary LADC, and that p63 and CD141 are sensitive for SCC. These results indicate that Napsin A is a promising marker for differential diagnosis of adenocarcinoma in the lung.
Category: Pulmonary

Wednesday, March 24, 2010 9:30 AM

Poster Session V # 246, Wednesday Morning

 

Close Window